STEFANI, ALESSANDRO
 Distribuzione geografica
Continente #
NA - Nord America 55.486
EU - Europa 3.818
AS - Asia 740
Continente sconosciuto - Info sul continente non disponibili 24
SA - Sud America 18
OC - Oceania 5
AF - Africa 1
Totale 60.092
Nazione #
US - Stati Uniti d'America 55.454
IE - Irlanda 1.000
UA - Ucraina 837
DE - Germania 512
CN - Cina 503
IT - Italia 355
FR - Francia 337
SE - Svezia 208
GB - Regno Unito 195
KR - Corea 144
FI - Finlandia 129
PL - Polonia 117
RU - Federazione Russa 62
CA - Canada 26
EU - Europa 23
BE - Belgio 21
JP - Giappone 21
IN - India 16
KG - Kirghizistan 13
VN - Vietnam 13
NL - Olanda 8
BR - Brasile 7
CL - Cile 7
UZ - Uzbekistan 6
CH - Svizzera 5
PT - Portogallo 5
AL - Albania 4
AU - Australia 4
BG - Bulgaria 4
ES - Italia 4
HK - Hong Kong 4
RO - Romania 4
DM - Dominica 3
GR - Grecia 3
MX - Messico 3
SG - Singapore 3
SK - Slovacchia (Repubblica Slovacca) 3
AT - Austria 2
CO - Colombia 2
IL - Israele 2
IQ - Iraq 2
IR - Iran 2
MY - Malesia 2
PE - Perù 2
TW - Taiwan 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AE - Emirati Arabi Uniti 1
AM - Armenia 1
BD - Bangladesh 1
BY - Bielorussia 1
CZ - Repubblica Ceca 1
EG - Egitto 1
GE - Georgia 1
ID - Indonesia 1
LA - Repubblica Popolare Democratica del Laos 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
SA - Arabia Saudita 1
Totale 60.092
Città #
Wilmington 15.908
Houston 15.105
Woodbridge 14.022
Fairfield 2.261
Ann Arbor 1.123
Ashburn 952
Seattle 873
Jacksonville 768
Cambridge 767
Chandler 726
Dublin 660
Medford 509
Dearborn 413
Beijing 261
Lawrence 235
Rome 142
New York 118
San Diego 115
Kraków 110
Menlo Park 110
London 50
Mülheim 49
Norwalk 44
Redwood City 40
Zhengzhou 37
Milan 32
Hefei 30
Seoul 28
Palo Alto 27
Durham 26
Verona 25
Shanghai 22
Brussels 21
Falls Church 21
Kunming 21
Nanjing 21
Mountain View 20
Toronto 19
University Park 19
Phoenix 16
St Louis 16
San Jose 15
Creede 14
Kilburn 12
Mcallen 12
Saint Petersburg 12
Helsinki 11
Hounslow 11
Redmond 11
Chengdu 10
Engelhard 10
Jinan 10
Monmouth Junction 10
Detroit 9
Guangzhou 9
Dong Ket 8
Garden City 8
Hangzhou 8
Boardman 7
Campi Bisenzio 7
Pune 7
Atlanta 6
Chiswick 6
Council Bluffs 6
Del Norte 6
Edinburgh 6
Hattiesburg 6
Islington 6
San Mateo 6
Shenyang 6
Warsaw 6
Hanoi 5
Nanchang 5
Philadelphia 5
Reggio Calabria 5
Tokyo 5
Wuhan 5
Changsha 4
New Bedfont 4
Palermo 4
Quzhou 4
Santarém 4
St. George 4
São Paulo 4
Augusta 3
Bielefeld 3
Chicago 3
Chongqing 3
Como 3
Florence 3
Fuzhou 3
Indiana 3
Kolkata 3
Los Angeles 3
Montréal 3
Naples 3
Nürnberg 3
Poniky 3
Roseau 3
Rosny-sous-bois 3
Totale 56.129
Nome #
CSF biomarkers, impairment of cerebral hemodynamics and degree of cognitive decline in Alzheimer's and mixed dementia 437
Spontaneous sleep modulates the firing pattern of Parkinsonian subthalamic nucleus 434
AD with subcortical white matter lesions and vascular dementia: CSF markers for differential diagnosis 427
Action of GP 47779, the active metabolite of oxcarbazepine, on the corticostriatal system. I. Modulation of corticostriatal synaptic transmission 424
AD with subcortical white matter lesions and vascular dementia: CSF markers for differential diagnosis. 424
Cerebrospinal-fluid Alzheimer's Disease Biomarkers and Blood-Brain Barrier Integrity in a natural population of cognitive intact Parkinson's Disease patients. 420
Selective vulnerability of pallidal neurons in the early phases of manganese intoxication 415
Autonomic Function Tests and MIBG in Parkinson's Disease: Correlation to Disease Duration and Motor Symptoms 415
Differential post-translational modifications of transthyretin in Alzheimer's disease: A study of the cerebral spinal fluid. 414
The pharmacological blockade of medial forebrain bundle induces an acute pathological synchronization of the cortico-subthalamic nucleus-globus pallidus pathway. 411
Acute inactivation of the medial forebrain bundle imposes oscillations in the SNr: a challenge for the 6-OHDA model? 411
Acute nigro-striatal blockade alters cortico-striatal encoding: An in vivo electrophysiological study 411
Bilateral deep brain stimulation of the pedunculopontine and subthalamic nuclei in severe Parkinson's disease 410
Homovanillic acid in CSF of mild stage Parkinson's disease patients correlates with motor impairment 410
Increased blood-cerebrospinal fluid transfer of albumin in advanced Parkinson's disease 409
Different TMS patterns of intracortical inhibition in early onset Alzheimer dementia and frontotemporal dementia 409
Strength and weaknesses of cerebrospinal fluid biomarkers in Alzheimer's disease and possible detection of overlaps with frailty process 404
Biochemical and electrophysiological changes of substantia nigra pars reticulata driven by subthalamic stimulation in patients with Parkinson's disease 404
Deep brain stimulation of CM/PF of thalamus could be the new elective target for tremor in advanced Parkinson's Disease? 403
Tetrabenazine improves levodopa-induced peak-dose dyskinesias in patients with Parkinson's disease 402
Cardiac sympathetic denervation is not related to nigrostriatal degeneration in Parkinson's disease 401
Magnetic resonance imaging markers of Parkinson's disease nigrostriatal signature 400
Distinct roles of cortical and pallidal β and γ frequencies in hemiparkinsonian and dyskinetic rats 399
Deficient vesicular storage: A common theme in catecholaminergic neurodegeneration 397
The clinical efficacy of L-DOPA and STN-DBS share a common marker: reduced GABA content in the motor thalamus 395
Deep brain stimulation of pedunculopontine tegmental nucleus: role in sleep modulation in advanced Parkinson disease patients: one-year follow-up. 393
Tetrabenazine improves levodopa-induced peak-dose dyskinesias in patients with Parkinson's disease 393
Opioid-mediated modulation of calcium currents in striatal and pallidal neurons following reserpine treatment: focus on kappa response. 391
Posterior cortical atrophy with unilateral occipito-temporal degeneration 388
Differential post-translational modifications of transthyretin in Alzheimer's disease: A study of the cerebral spinal fluid. 387
Stimulation of the subthalamic nucleus compared with the globus pallidus internus in patients with Parkinson disease 387
Bilateral GPi DBS is useful to reduce abnormal involuntary movements in advanced Parkinson's disease patients, but its action is related to modality and site of stimulation 386
Reasons driving treatment modification in Parkinson's disease: results from the cross-sectional phase of the REASON study. 385
Deep brain stimulation of both subthalamic nucleus and internal globus pallidus restores intracortical inhibition in Parkinson's disease paralleling apomorphine effects: a paired magnetic stimulation study 385
Therapy for dyskinesias in Parkinson’s disease patients 385
Subthalamic stimulation and levodopa modulate cortical reactivity in Parkinson's patients 385
Electrophysiology of dopamine D-1 receptors in the basal ganglia: old facts and new perspectives 384
Pathological gambling from dopamine agonist and deep brain stimulation of the nucleus tegmenti pedunculopontine 384
Helicobacter pylori eradication and l-dopa absorption in patients with PD and motor fluctuations 384
Sad and happy facial emotion recognition impairment in progressive supranuclear palsy in comparison with Parkinson's disease 383
Serotonin impairment in CSF of PD patients, without an apparent clinical counterpart 383
Altered profile and D2-dopamine receptor modulation of high voltage-activated calcium current in striatal medium spiny neurons from animal models of Parkinson's disease. 382
Action of GP 47779, the active metabolite of oxcarbazepine, on the corticostriatal system. II. Modulation of high-voltage-activated calcium currents 382
Different patterns of nigrostriatal degeneration in tremor type versus the akinetic-rigid and mixed types of Parkinson's disease at the early stages: molecular imaging with 123I-FP-CIT SPECT 382
Vulnerability of medium spiny striatal neurons to glutamate: role of Na+/K+ ATPase 381
The impact of rotigotine on cardiovascular autonomic function in early Parkinson's disease. 379
Pedunculopontine nucleus stimulation influences REM sleep in Parkinson's disease 377
A field potential analysis on the effects of lamotrigine, GP 47779, and felbamate in neocortical slices 376
Neurotensin effects on N-type calcium currents among rat pallidal neurons: an electrophysiological and immunohistochemical study. 376
Rasagiline effect on bladder disturbances in early mild Parkinson's disease patients 374
Outward potassium currents activated by depolarization in rat globus pallidus 374
Thalamic ¹²³I FP-CIT uptake in a patient with clinical diagnosis of Parkinson's disease and depression 373
Activation of metabotropic glutamate receptors inhibits calcium currents and GABA-mediated synaptic potentials in striatal neurons 370
Association analysis between Alzheimer's disease and the Nicastrin gene polymorphisms 369
Subthalamic stimulation activates internal pallidus: evidence from cGMP microdialysis in PD patients 368
In vivo electrophysiology of dopamine-denervated striatum: focus on the nitric oxide/cGMP signaling pathway. 368
The modulation of dopamine receptors in rat striatum 366
D2-mediated modulation of N-type calcium currents in rat globus pallidus neurons following dopamine denervation 364
The modulation of calcium currents by the activation of mGluRs. Functional implications 360
The early course of affective and cognitive symptoms in de novo patients with Parkinson's disease 360
Catecholamine-based treatment in AD patients: expectations and delusions 360
Electrophysiology of sipatrigine: a lamotrigine derivative exhibiting neuroprotective effects 359
Rotigotine effect on sleep in a de novo Parkinson's Disease patient affected by periodic limb movement disorder 359
Motor and non-motor effects of PPN-DBS in PD patients: insights from intra-operative electrophysiology 358
Alexithymia is a non-motor symptom of Parkinson disease 357
Hemodynamic changes in Alzheimer's disease: A leading role behind the courtain? Commentary on "CSF Aβ1-42 combined with neuroimaging biomarkers in the early detection, diagnosis and prediction of Alzheimer's disease" by Lista et al 356
Theta Burst Stimulation Modulates Cerebellar-Cortical Connectivity in Patients with Progressive Supranuclear Palsy 355
Efficacy and safety profile of prolonged release oxycodone in combination with naloxone (OXN PR) in Parkinson’s disease patients with chronic pain 354
Basic research in substantia nigra and ventral tegmental area: clinical implications 353
Deep brain stimulation in Parkinson's disease patients: biochemical evidence 352
Bilateral deep brain stimulation of the pedunculopontine and subthalamic nuclei in severe Parkinson's disease. 350
Low frequency stimulation of the nucleus tegmenti pedunculopontini increases cortical metabolism in parkinsonian patients 350
CSF and clinical hallmarks of subcortical dementias: focus on DLB and PDD 349
Subdyskinetic apomorphine responses in globus pallidus and subthalamus of parkinsonian patients: lack of clear evidence for the 'indirect pathway' 349
CSF markers in Alzheimer disease patients are not related to the different degree of cognitive impairment 348
Successful subthalamic stimulation, but levodopa-induced dystonia, in a genetic Parkinson's disease 347
Helicobacter pylori eradication and l-dopa absorption in patients with PD and motor fluctuations.(Reply from the authors) 347
Different patterns of cardiac sympathetic denervation in tremor-type compared to akinetic-rigid-type Parkinson's disease: molecular imaging with ¹²³I-MIBG. 347
Re: Stereotactic microdialysis of the basal ganglia in Parkinson's disease 347
The effect of deep brain stimulation on the frontal N30 component of somatosensory evoked potentials in advanced Parkinson's disease patients 346
Microdialysis in Parkinsonian patient basal ganglia: acute apomorphine-induced clinical and electrophysiological effects not paralleled by changes in the release of neuroactive amino acids 343
Cerebrospinal fluid lactate levels and brain [18F]FDG PET hypometabolism within the default mode network in Alzheimer’s disease 341
Deep brain stimulation of the pedunculopontine tegmentum and subthalamic nucleus: effects on gait in Parkinson's disease 339
Lowered cAMP and cGMP signalling in the brain during levodopa-induced dyskinesias in hemiparkinsonian rats: new aspects in the pathogenetic mechanisms 339
L-dopa modulates motor cortex excitability in Alzheimer's disease patients 338
Association study of the 5-hydroxytryptamine(6) receptor gene in Alzheimer's disease 338
Electrophysiological actions of felbamate on rat striatal neurones 336
Reduced GABA Content in the Motor Thalamus during effective deep brain stimulation of the subthalamic nucleus 330
Rotigotine may improve sleep architecture in Parkinson's disease: a double-blind, randomized, placebo-controlled polysomnographic study. 330
Deep brain stimulation of pedunculopontine tegmental nucleus (PPTg) promotes cognitive and metabolic changes: a target-specific effect or response to a low-frequency pattern of stimulation? 327
CSF biomarker variability in the Alzheimer's Association quality control program 327
Implantation of the nucleus tegmenti pedunculopontini in a PSP-P patient: safe procedure, modest benefits 326
The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers 325
Cardiac rhabdomyosarcoma: a clinicopathologic and electron microscopy study 322
Multi-target strategy for Parkinsonian patients: the role of deep brain stimulation in the centromedian-parafascicularis complex. 322
Does 123I-MIBG scintigraphy really assist the diagnosis of Parkinson's disease? 322
Antiparkinsonian and anti-levodopa-induced dyskinesia effects obtained by stimulating the same site within the GPi in PD 322
Rasagiline effect on bladder disturbances in early mild Parkinson's disease patients 321
Grammar improvement following deep brain stimulation of the subthalamic and the pedunculopontine nuclei in advanced Parkinson's disease: A pilot study 320
Neuroacanthocytosis associated with a defect of the 4.1R membrane protein 319
Totale 37.180
Categoria #
all - tutte 115.535
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 115.535


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20193.023 0 0 0 0 0 0 0 0 0 0 1.485 1.538
2019/202020.273 1.272 1.835 1.569 2.045 1.804 2.177 1.724 1.815 1.804 1.655 1.206 1.367
2020/202110.978 1.309 1.390 1.315 1.352 1.062 1.219 1.240 1.008 256 211 514 102
2021/20222.888 60 357 142 125 89 153 613 148 136 143 238 684
2022/20232.237 277 161 80 219 170 611 251 124 170 6 120 48
2023/2024709 93 34 67 19 88 149 36 144 22 57 0 0
Totale 61.002